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During 2004 to 2011, 81, 420, and 166 patients with colorectal cancer (CRC), epithelial appendiceal neoplasm (APN), and gastric
cancer (GC) with PC were treated with cytoreductive surgery (CRS) plus perioperative chemotherapy. CRS was performed by
peritonectomytechniquesusinganaquadissection.Results.Completecytoreductionwasdonein62/81(76.5%),228/420(54.3%),
and 101/166 (60.8%) of patients with CRC, APN, and GC. The main reasons of incomplete resections were involvement of all
peritoneal regions and diﬀuse involvement of small bowel. The incidence (64%, 302/470) of CC-0 resection after introduction of
an aqua dissection was signiﬁcantly higher than before (42%, 82/197). A total of 41 (6.1%) patients died postoperatively. Major
complication (grade 3-4 complications) occurred in 126 patients (18.9%). A reoperation was necessary in 36 patients (5.4%). By
the multivariate analysis, PCI scores capable of serving as thresholds for favorable versus poor prognosis in each group and CC
scores demonstrated as the independent prognostic factors. Conclusions. Peritonectomy using an aqua dissection improves the
incidence of complete cytoreduction, and improves the survival of patients with PC. Patients with PCI larger than the threshold
values should be treated with chemotherapy to improve the incidences of complete cytoreduction.
1.Introduction
The current state-of-the-art treatment for the peritoneal
carcinomatosis (PC) from colorectal, appendiceal, and
gastric cancers consists of a comprehensive management
strategy using cytoreductive surgery (CRS) and perioper-
ative intraperitoneal chemotherapy (PIC) [1–5]. Patients
with a low tumor volume, well/moderately diﬀerentiated
tumors, and complete cytoreduction may potentially beneﬁt
from combined treatment. No survival beneﬁt has been
reported by cytoreduction alone [3]. In contrast, CRS plus
hyperthermic intraoperative intraperitoneal chemotherapy
(HIPEC) confers a prolonged survival period [2, 3]. Among
several prognostic factors, complete cytoreduction is the
most important prognostic factor for a good outcome [1–3].
However, complete cytoreduction is sometimes diﬃcult
in patients with deep invasion into the liver hilum, lesser
omentum, pelvic structures, liver parenchyma, or diﬀuse
involvement of the mesentery and serosa of small bowel.
Even by the most experienced surgeons in the world, the
incidences of complete cytoreduction are reported 77%
(617/802) [4]. However, the complete cytoreduction rate
depends on the selection criteria for the CRS and the ability
and experiences of the surgeons. In the present paper, our2 Gastroenterology Research and Practice
surgical techniques for the complete yet safe cytoreduction
and the results after CRS will be reported; 81 (42.9%), 420
(72.7%) and 166 (51.5%).
2. Patientsand Methods
2.1. Patients. Between June, 2004, and January, 2011, a
total of 667 patients underwent CRS combined with PIC
for peritoneal carcinomatosis from colorectal origin (N =
81), epithelial appendiceal neoplasm (N = 420), and gastric
cancer (N = 166), led by a single surgeon (Y. Yonemura)
at Kishiwada Tokushukai and Kusatsu General Hospital,
Japan. The included patients were >19 and, <87 years old,
with good performance status (World Health Organization
Performance Status ≤2). All patients underwent extensive
preoperative investigations, which included physical exami-
nation and abdominal, pelvic, and chest computed tomogra-
phy(CT)scanstoassesstheextentofthediseaseinvolved.CT
scans were performed following the administration of oral
and intravenous contrast media. Signed informed consent
was obtained from all patients.
2.2. Quantitative Evaluation of the Volume of PC and
Assessment Completeness of Cytoreduction. Preoperatively,
the tumor volume was quantiﬁed according to computed
tomography (CT) scans using the Peritoneal Cancer Index
(PCI,WashingtonCancerInstitute)[6,7].Theabdomenand
pelvis were divided into nine regions and the small bowel
into four: each assigned a lesion size (LS) score of 0–3,
representative of the largest implant visualized. LS-0 denotes
the absence of implants, LS-1 indicates implants <0.25cm,
LS-2 implants between 0.25 and 5cm, and LS-3 implants
>5cm or a conﬂuence of disease. These ﬁgures amount to
a ﬁnal numerical score of 0–39.
2.3. Selection Criteria for CRS. CRS consists of numerous
surgical procedures depending on the extent of peritoneal
tumor manifestation. Surgery may include parietal and
visceral peritonectomy, greater and lesser omentectomy,
splenectomy, cholecystectomy, resection of the liver capsule,
small bowel resections, colonic and rectal resections, gastrec-
tomy, pancreatic resection, hysterectomy, ovariectomy, and
urine bladder resection [8].
Patients who had the following criteria are excluded
as candidates for peritonectomy: (1) evidence of lymph
node involvement and distant hematogenous metastasis
conﬁrmed by computed tomography (CT), magnetic res-
onance imaging (MRI), or 18Fluorodeoxyglucose positron
emissiontomography(PET/CT),(2)progressivediseaseafter
preoperative chemotherapy, and (3) severe comorbidities or
poor general condition.
2.4. Methods of CRS Using Peritonectomy Techniques
2.4.1. Dissection Techniques of CRS. Under general anesthe-
sia,midline incision wasmadefromthexiphoidto thepubis,
and PCI score was calculated in each case [8, 9].
For the tissue dissection, electrosurgical techniques are
used. In electrosurgery, a generator delivers high frequency
current greater than 200kHz under high power electric-
ity (100Watt), and the tissue impedance converts electric
current into thermal energy, resulting in the localized
tissue heating and coagulation. We use the electrosurgical
generator (Valleylab Inc., Boulder, CO, USA), on pure cut
and adjusted to the maximum electrical power. The mainly
used handpiece is the ball-tipped type. The 2mm ball-tip
electrode is used for dissecting on visceral surfaces, including
stomach, small bowel, and colon. When more rapid tumor
destruction is required, the 5mm ball-tip can be used.
Before the tissue dissection with electrosurgery, a 5%
dextran solution plus adrenaline (a concentration of 10−6)
is injected into the dissection plane to separate the layers
properly and to decrease bleeding. The technique is named
the aqua dissection method and was started in January, 2008.
Theball-tippedinstrumentisplacedattheinterfaceoftumor
and normal tissues. The focal point for further dissection is
placed on strong traction.
2.4.2. Peritonectomy for Parietal Peritoneum. The skin inci-
sion deepened through the linea alba till reaching the
extraperitoneal fat layer without opening the peritoneum.
Then, both sides of the parietal peritoneum are peeled oﬀ
from the posterior rectus sheath by the traction of the skin
using stay silk sutures and anchoring the edge of the skin to
theringframeoftheMunsterretractor.Astheplanebetween
the posterior rectus sheath and peritoneum is loose in the
areainferiortothearcuateline,thedissectionisstartedinthe
lower parietal peritoneum. Then, the dissection between the
peritoneum and the transversalis fascia is continued to the
retroperitoneal space. The dissection continues deeply and
in a counterclockwise direction, starting in the right ﬂank
till reaching the peritoneum covering the left cupula of the
diaphragm. Then, the dissection is completed in the upper
right side till reaching the anterior renal fascia, inferior vena
cava, and posterior wall of the duodenum.
The peritoneum of the Morrison pouch and paracolic
gutters on both sides is completely freed from retroperi-
toneum and is removed with the anterior parietal peri-
toneum. The ureters and gonadal vessels are identiﬁed and
taped. In males, the gonadal vessels should be preserved but
are removed with the ovary in females.
The dissected parietal peritoneum is opened in the
midline, and extensive wash and aspiration of the peritoneal
cavity ten times using one liter of normal saline each time
is done. The purpose of the washing is to remove peritoneal
free cancer cells and mucinous materials from the peritoneal
cavity. During the washing surgeons decide the operation
plan.
2.4.3. Peritonectomy of the Undersurface of Diaphragm. If the
undersurface of the diaphragm is involved, stripping of peri-
toneum from the right and left hemidiaphragm is done. The
falciform and round ligament are taken down and resected
completely. Bleeding from diaphragmatic muscle is stopped
by argon beam coagulation (ABC) which has a penetrationGastroenterology Research and Practice 3
Figure 1: Cancer cells tend to invade the muscle layer of the encir-
cledareaoftherighthemidiaphragm,whereistheboundaryofbare
area and peritoneal reﬂection. Bare area below the invaded.
Figure 2: Partial resection of the diaphragm by using a linear
stapler.
depthofcoagulationlimitedtoafewmillimeters.Advantages
of ABC include the ability to coagulate broad surface areas
and larger vessels.
Figure 1 shows the area where cancer cells tend to invade
into the muscle layer of the right hemidiaphragm. After
the blunt dissection of the posterior space of the invaded
diaphragm with ﬁnger between diaphragm and the bare
area, partial resection of the full thickness of the right
diaphragmatic cupula inﬁltrated by tumor is excised using
a linear stapler (Figure 2). The staple line is then reinforced
with an absorbable suture material.
2.4.4. Perigastric Peritonectomy. A greater omentectomy is
performed with combination of splenectomy and the resec-
tion of anterior leaf of mesocolon. If the omentum is free
of disease, gastroepiploic arcade is preserved after taping
the root of the vessels. Greater omentum is removed with
the right gastroepiploic vessels if it is involved with bulky
tumor. Splenic artery and vein are identiﬁed and ligated
at the splenic hilum. If the right gastroepiploic vessels and
spleen are removed, left gastric artery and vein should be
preserved. After the left lobe of the liver is freed from the
left triangular ligament, resection of the lesser omentum
along the Arantius duct is started. Next the small incisions
are made on the peritoneal attachment to the stomach
Left gastric vessels
Antrum
Figure 3: A 5% dextrose solution is injected in the incision site on
the lesser curvature, and the left gastric vessels are identiﬁed and
taped. Aqua dissection technique.
Figure 4: Preservation of the left gastric vessels and whole stomach.
Surgical techniques of the removal of lesser omental tumors.
wall, and the 5% dextran solution is injected through
the incision (aqua dissection technique), resulting in the
separation of lesser omental tumor from the left gastric
vessels. In the appendiceal tumor and colorectal cancer, the
boundary between tumor and normal tissue is clear, and
the omental tumors can be easily removed by the traction
of the taped vessels (Figures 3 and 4). The whole stomach
is preserved by the preservation of the left gastric vessels
without perforation.
Except for gastric cancer, gastrectomy may be sometimes
indicated in patients with peritoneal carcinomatosis from
PMP, colorectal cancer, ovarian cancer, and mesothelioma
[6, 7]. The reason of gastrectomy is the tumor invasion
into the gastric wall. The parts of gastric wall liable to
involvement by the disease process are (1) the posterior wall
of the antrum in the vestibule of the omental bursa, (2) the
mid-lesser curvature, which are invaded from the metastasis
of lesser omentum, and (3) the upper greater curvature
by the invasion from splenic hilar metastasis (Figure 5). In
PMP, almost all invasions are limited in the muscle layer
of stomach. If the invasion into the stomach wall is less
than 5cm in diameter, a seromuscular resection or a wedge
resection of the whole layer of the stomach using stapler
techniques is recommended. Surgeons should decide the4 Gastroenterology Research and Practice
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Figure 5: The parts of gastric wall liable to involvement by the
disease process (dotted line): (1) the posterior wall of the antrum
in the vestibule of the omental bursa, (2) the mid-lesser curvature,
which are invaded from the metastasis of lesser omentum, and
(3) the upper greater curvature by the invasion from splenic hilar
metastasis. Region 4 is named as superior omental recessus, which
is frequently involved in pseudomyxoma peritonei.
Figure 6: Enhanced CT scan shows tumor located in the hilar,
cystic,andumbilicalplate,andtumorextendedinGlisson’scapsule.
necessity of the gastrectomy from the arterial supply for the
residual stomach, the areas of invasion, and residual part of
the stomach. Importantly, the small bowel should be intact
for the safe reconstruction either by esophagojejunostomy or
gastrojejunostomy.
2.4.5. Perihepatic Peritonectomy. In PC from PMP and
mucinous ovarian tumors, hepatoduodenal ligament and
liver hilar plate are frequently involved (Figures 6 and 7).
The plate system is formed at the level of the liver hilum
by coalescence and thickening of Glisson’s capsule and
vasculobiliary sheaths. This plate system is divided into three
parts of connective thickening: the hilar plate that separates
the biliary conﬂuence from the inferior part of the quadrate
lobe (S4b), the cystic plate that envelops the gallbladder and
cystic duct, and the umbilical plate that covers the umbilical
portion of the portal vein (Figure 7).
Figure 6 shows the enhanced CT scan showing the tumor
locatedinthehilar,cystic,andumbilicalplatesandthetumor
extended in Glisson’s capsule.
The only eﬃcient procedure for hilar metastases is
excision, which is followed by complementary treatment.
Surgery should start with the dissection of the hepatodu-
odenal ligament, to identify the limits of the tumor, its
mobility, or inﬁltration of adjacent planes and elements,
Hilar plate Umbilical plate
Choledochus
(a)
Cystic plate
Hilar plate
Umbilical plate
Common bile duct
Hepatic artery
Portal vein
(b)
Figure 7: The view of the hilar plate after complete eradication of
the inﬁltrating tumor. The right portal pedicle is tapped by blue
tape. The oozing blood from the liver surface is controlled by ABC.
Dissection of mucinous tumor from the hilar plate after taping the
right portal pedicle branches. This excision only involves surgical
removal of Glisson’s capsule bearing tumor and approximately 1-
2cm in depth of hepatic parenchyma.
conﬁrmingtheexistenceorabsenceofinﬁltrationofvascular
elements and, in particular, of the portal vein or its branches.
Dissectionofthehepaticpedicleusuallybeginswithisolation
of the artery followed by the biliary tract and portal vein.
Aqua dissection enables to identify the second branches of
the portal triads (Figure 7). The gall bladder is removed.
Lesser omentum is excised routinely. The attachment of
the lesser omentum to the caudate lobe and ligamentum
venosum is excised and the omental bursa is exposed. The
leftgastricarteryandveinareidentiﬁedandtaped.Thelesser
omentum is taken all the way from the lesser curvature to the
caudate lobe and ligamentum venosum by preserving the left
and right gastric vessels.
As shown in Figure 8, axial contrast-enhanced CT scan
of the upper abdomen demonstrates multiple low attenuated
cystic lesions with rim-like calciﬁcations scalloping the liver
margin, inﬁltrating the spleen, and compressing the bowel,
pancreas, and left kidney. To remove such lesions, liver
capsule near the lesions is cut with electrocautery, and
the space between the capsule of the scalloping lesion and
liver parenchyma is dissected with scalpel by making a
countertractionoftumors.Figure 9showstheoperativeview
a n dr e s e c t e ds p e c i m e na f t e re n u c l e a t i n go fal a r g ec y s t i c
lesion indents the liver deeply.
Peritoneum of the superior omental recess (region 4 in
Figure 5), which occupies the caudate lobe, diaphragmatic
crus, and anterior wall of vena cava, is removed.Gastroenterology Research and Practice 5
Figure 8: Axial contrast-enhanced CT scan of the upper abdomen
demonstrates multiple low attenuated cystic lesions with rim-like
calciﬁcations scallopingthelivermargin,inﬁltratingthespleen,and
compressing the bowel, pancreas, and left kidney.
(a)
(b)
Figure 9: The operative view after enucleating of a large cystic le-
sion indenting the liver deeply. The resected specimen of the lesion
described in Figure 8.
Figure 10 shows the tumors in the superior omental
recess. By traction of tumors to left side, the capsule of
caudate lobe is cut and the tumors with liver capsule and
retroperitoneum are peeled oﬀ from the caudate lobe, left
crural muscle, and vena cava.
Morrison’s pouch and the paracolic gutter are the
common sites of tumor implantation. The peritoneum
covering Morrison’s pouch is removed with the peritoneum
on the right paracolic gutter, right subdiaphragm, and right
abdominal wall (Figures 11 and 12).
Large tumors attach on the ascending colon and hepatic
ﬂexure, and tumors on the paracolic gutter and Morrison’s
pouch are removed in combination with extended right
hemicolectomy.
Figure 10: Coronal enhanced CT scan shows tumor located
between the inferior vena cava, caudate lobe, and left crus of
diaphragm.
(a)
Caudate lobe
Tumor
Common hepatic artery
Pancreas
(b)
Figure 11: Dissection of the tumor in the superior omental
recessus. By traction of tumors to the left side, the capsule of
the caudate lobe is cut and the tumors with liver capsule and
retroperitoneum are dissected from the caudate lobe, left crural
muscle, and vena cave.
2.4.6. Pelvic Peritonectomy. The entire pelvic peritoneum is
dissected from the anterior inferior abdominal wall, urinary
bladder, and retroperitoneum. The peritoneum covering the
urinary bladder is dissected, and the rectovesical pouch is
completely freed from the urinary bladder and rectum. In
males, the space between the seminal vesicle and peritoneum
of rectovesical pouch is dissected, lifting the vas deferens
oﬀ. In females, blood vessels around the uterus are dissected
and cut with Ligasure (Valleylab Inc., Boulder, CO, USA).6 Gastroenterology Research and Practice
Right adrenal gland
Right kidney
(a)
Right kidney
(b)
Figure 12: Dissection line of Morrison’s pouch. The peritoneum
covering Morrisons’s pouch is removed with the peritoneum on
the right paracolic gutter, right subdiaphragm, and right abdominal
wall.
Amputation of the vagina is done at a plane 1cm below
the peritoneal reﬂection of the Douglass pouch to ensure
removal of all tumors occupying the cul-de-sac.
Ifthetumorinvadestheanteriorrectalwall,therectumis
cutat1cmbelowtheperitonealreﬂection.Reasonablelength
of the rectum should be preserved for the anastomosis with
the colon or ileum.
2.4.7. Peritonectomy of Small Bowel. The entire small bowel
anditsmesenteryaretracedfromtheduodenojejunalﬂexure
to the ileocecal junction. There are often tumor nodules at
paraduodenal recesses covering the ligament of Treitz, and
theseareeasilydissectedbytheaquadissectiontechniqueand
resectedaswellasanyothertumoralongtheway.Then, both
sides of the mesentery are inspected and palpated and the
tumor nodules excised with electrosurgery.
Completecytoreductionisaimedbyremovingallmacro-
scopic tumors by peritonectomy combined with laser or
electric fulguration and HIPEC for microscopic PC.
2.4.8. Assessment of Completeness of Cytoreduction. The aim
of CRS was to obtain complete macroscopic cytoreduction
as a precondition for the application of HIPEC. The residual
diseasewasclassiﬁedintraoperativelyusingthecompleteness
of cytoreduction (CC) score [9]. CC-0 indicates no visible
residual tumor, CC-1 indicates residual tumor nodules
≤2.5mm, CC-2 indicates residual tumor nodules between
2.5mm and 25mm, and CC-3 indicates residual tumor
nodules >25mm or a conﬂuence of unresectable tumor
nodules at any site within the abdomen and the pelvis. CC-2
and CC-3 cytoreductions are regarded incomplete.
2.5.StatisticalAnalyses. Allpatientswerefollowedupandno
patients were lost to follow up. Outcome data were obtained
from medical records and patients’ interviews. All statistical
analyses were performed using the SPSS software statistical
computer package version 17 (SPSS Inc., Chicago, USA).
3. Results
3.1. Completeness of Cytoreduction. CC-0,-1 resections were
done in 62/81 (76.5%), 228/420 (54.3%), and 101/166
(60.8%) of patients with colorectal cancer, appendiceal
neoplasm, and gastric cancer (Table 1). CC-0,-1 resections
of colorectal and appendiceal neoplasm patients with PCI ≤
20 were performed in 89.4% (59/66) and 86.2% (168/195),
but that in gastric cancer patients was done only in 67.6%
(100/148). In contrast, 5.6% of gastric cancer patients with
PCI ≥ 20 underwent CC-0,-1 resections (1/18), but CC-0,-
1 resections in colorectal and appendiceal neoplasm patients
wereperformedin20.0%(3/15)and26.6%(60/165),respec-
tively. One gastric cancer patient underwent CC-0 resection
for PCI score of 32 which was mucinous adenocarcinoma.
The reasons of CC-2,-3 resections are listed in Table 2.
Themostfrequentreasonswereinvolvementofallperitoneal
regions (N = 89) and diﬀuse involvement of small bowel
serosa or mesentery (N = 113). In appendiceal neoplasms,
massive bleeding more than 5L was the reason to stop
operation (N = 10). Old age (N = 6) and comorbidities
(N = 4) are also the reasons of CC-2,-3 resections. In
appendiceal neoplasms, 6 patients with massive scalloping
to the liver hilum or parenchyma showed the reason of
CC-2,-3 resections. In gastric cancers, local invasion to
the surrounding organs from the primary tumor, positive
surgical margin at the esophageal or duodenal stump, and
distant lymph node metastasis were found in 6, 3, and 3
patients.
Regarding the correlation between PCI scores of small
bowel (SB-PCI) and CC scores in colorectal cancer patients,
CC-0,-1 resection was done in 36 of 38 (95%) patients
with SB-PCI ≤ 3, but only in 12 of 24 (50%) patients with
SBPCI ≥ 4.Gastroenterology Research and Practice 7
Table 1: Correlation of CC scores and PCI scores.
PCI ≤ 10 11 ≤ PCI ≤ 20 21 ≤ PCI ≤ 30 PCI ≥ 31 Total
colorectal cancer
CC-0,-1 43 (95.5%) 16 (76.2%) 3 (30.0%) 0 (0.0%) 62 (76.5%)
CC-2,-3 2 5 7 5 19
Appendiceal
neoplasm
CC-0,-1 111 (97.4%) 57 (0.3%) 39 (36.4%) 21 (17.8%) 228 (54.3%)
CC-2,-3 3 24 68 97 192
Gastric cancer
CC-0,-1 95 (79.2%) 5 (21.7%) 0 (0.0%) 1 (25.0%) 101 (60.8%)
CC-2,-3 25 23 14 3 66
Table 2: The causes of CC-2,-3 resections.
Colorectal cancer Appendiceal neoplasm Gastric cancer
Involvement of all peritoneal regions 7 71 (22 + old age) 11
Diﬀuse small bowel involvement 5 (2 + LB#,1+P H $) 86 (15 + LB, 3 + PH,1 + ST&) 2 2( 1+L G )
Bleeding 0 10 0
Old age 1 5 0
Comorbidity 0 4 0
Positive histologic margin 0 0 6
Local invasion 0 2 3
Lymph node metastasis 0 0 3
Perihepatic involvement 0 6 0
Emergency 1 2 0
others 1 4 1
#LB: large bowel involvement, $PH: perihepatic involvement, and &ST: stomach involvement.
In gastric cancer patients, 65 of 78 (83%) of patients
with SB-PCI ≤ 3 and 43/83 (52%) of those with SBPCI ≥
4 underwent CC-0,-1 resections.
In PMP patients, CC-0,-1 resection rate was signiﬁcantly
higher in patients with SB-PCI ≤ 6 (209/265, 79%) than that
in those with SB-PCI ≥ 7 (19/155, 12%).
Before December, 2007 (ﬁrst 3 years), CC-0,-1 resection
was done in 82 (42%) of 197 patients. After January,
2008 (next 3 years), when the aqua dissection method was
introduced, it was done in 302 (64.3%) of 470 patients, and
there was a signiﬁcant diﬀerence (P<0.001). In the ﬁrst 3
years, complete cytoreduction was done in 14% (11/67) of
patients with PCI ≥ 29, but was done in 23.6% (29/122) in
the last 3 years.
3.2. Postoperative Mortality and Morbidity. A total of 41
(6.1%) among 667 patients died postoperatively. Mortality
rate (3.6%, 14/391) after CC-0,-1 resections was signiﬁcantly
lower than that (8.7%, 24/276) after CC-1,-2 resections
(Table 3). Causes of deaths were septic shock (N = 14),
ﬁstula and peritonitis (N = 12), multiple organ failure (N =
4), tumor progression (N = 4 ) ,l u n ge m b o l i s m( N = 2),
cardiac arrhythmia (N = 2), bleeding from duodenal ulcer
(N = 1), and massive abdominal bleeding (N = 1). There
was no diﬀerence between the complication rates and disease
categories.
Major complication (grade 3-4 complications) occurred
in 126 patients (18.9%). A reoperation was necessary in
36 patients (5.4%). The experienced complications were
abdominal abscess (N = 45), bowel ﬁstula (N = 19),
anastomosis or stump leakage (N = 18), ileus (N = 9),
leakagefromurinarybladder(N =8),perforationofstomach
(N = 6), abdominal bleeding (N = 5), bile leak (N = 3),
perforation of diaphragm (N = 3), respiratory failure (N =
3), renal failure (N = 1), arrhythmia (N = 1), bleeding from
duodenal ulcer (N = 1), and others (N = 4).
3.3.SurvivalafterCRS. Theoverall1-year,3-year,and5-year
survival rates and median survivals of the three groups are
shown in Table 4. Univariate analysis showed that the lymph
node status, tumor diﬀerentiation, gender, and performance
statusdidnothaveprognosticimpactonsurvival.The5-year
survival rates after CC-0,-1 resection for colorectal cancer,
appendiceal neoplasm, and gastric cancer patients were 28%,
84%, and 17%, respectively. In contrast, those in CC-2,-3
groups were 0%, 50%, and 2% respectively.
The 5-year survival rate of colorectalcancerpatients with
PCI score ≤ 10 was signiﬁcantly better than that with PCI
score ≥ 11 (P<0.001). In appendiceal cancer, patients with8 Gastroenterology Research and Practice
Table 3: Postoperative mortality and morbidity after cytoreductive surgery.
No complication Grades 1-2 Grade 3 Reoperation Hospital deaths
Colorectal cancer
CC-0,-1 35 (56.5%) 19 (30.1%) 3 (4.8%) 3 (4.8%) 2 (3.2%)
CC-2,-3 10 (52.6%) 3 (15.8%) 4 (21.0%) 0 2 (10.6%)
Appendiceal
neoplasm
CC-0,-1 128 (56.1%) 44 (19.3%) 32 (14.0%) 19 (8.3%) 5 (2.2%)
CC-2,-3 98 (51.0%) 26 (13.5%) 38 (19.8%) 10 (5.2%) 20 (10.4%)
Gastric cancer
CC-0,-1 76 (75.2%) 8 (7.9%) 9 (8.9%) 2 (2.0%) 7 (6.9%)
CC-2,-3 45 (68%) 10 (15.2%) 4 (6.1%) 2 (3.0%) 5 (7.6%)
PCI score ≤ 28 survived signiﬁcantly better than those with
PCI score ≥ 29 (P<0.001). Five-year survival rate of gastric
cancer patients with PCI score ≤ 6 was signiﬁcantly better
than that of patients with PCI score ≥ 7( Table 4).
By the multivariate analysis, PCI scores were capable of
serving as thresholds for favorable versus poor prognosis in
each group and CC scores demonstrated as the signiﬁcant
independent prognostic factors after CRS. In colorectal
cancer patients, CC score (CC-0,1 versus CC-2,-3) and
PCI score (PCI ≤ 10 versus PCI ≥ 11) emerged as the
independent prognostic factors (P = 0.031, P = 0.0016). RR
of patients with CC-2,3 versus CC-0,-1 was 4.63, and that of
patients with PCI ≥ 11 versus those with PCI ≤ 10 was 9.98.
In gastric cancer patients, CC score (CC-0,-1 versus CC-2,3)
was an only independent prognostic factor (P<0.05, X2 =
68.47, RR = 26.5).
4. Discussion
Current surgical management of the PC can be performed
with curative intent and potential long-term survival when
a strategy of CRS combined with HIPEC is used to select
patients.
Adequate patient selection and the improvement of
surgical skills of surgeons are crucial to obtain a complete
macroscopic cytoreduction, which is a leading predictor of
patient outcome. Adequate patient selection is sometimes
diﬃcult for surgeons with experience of small number of
cases with PC. Many criteria have to be assessed in each
patient: performance status, response to chemotherapies,
existence of lymph node and/or hematogenous metastasis,
histologic grading, PCI, and comorbidities. Patients with
poor performance status, severe comorbidities, and PC
already spread to the entire peritoneal cavity are not indi-
cated for complete cytoreduction. In gastric cancer, response
after neoadjuvant chemotherapy is one of the selection
criteria for CRS [5].
In the surgical treatment of patients with PC from
colorectal cancer, appendiceal neoplasm, and gastric cancer,
complete cytoreduction is believed as an essential factor for
a good prognosis. In the present data, CC-0,-1 and the PCI
scoresoflessthanthethresholdvaluesforeachdiseaseclearly
were demonstrated as independent prognostic factors after
CRS plus perioperative chemotherapy. Peritonectomy tech-
niques improved the incidence of complete cytoreduction,
as compared with the ordinary surgical techniques [6, 9–
12]. However, patients often with advanced metastases and
a limited life span undergo a comprehensive therapy of
multivisceral resection with several intestinal anastomosis
and HIPEC. Surgeons are required to safely perform com-
plete macroscopic tumor resection extended across several
surgical disciplines, including general surgery, hepatobiliary
surgery,urology,andgynecology.Theincidencesofcomplete
cytoreduction for colorectal cancer, appendiceal neoplasm
and gastric cancer in the present paper were 76.5%, 54.3%
and 60.8%, respectively. The values appeared reasonable as
compared with the results of other big centers [1, 4, 11,
13]. The incidences of complete cytoreduction for colorectal
cancer, appendiceal neoplasm, and gastric cancer were
reported as 49% ∼ 54% (50/102, 271/506) [1, 11], 73.6%
(577/783) [4], and 53% (85/159) [13], respectively. The
incidences of complete cytoreduction are mainly depending
on the surgeons’ experiences. A learning curve had been
already reported by several authors [12, 14, 15]. Moran et
al. reported a decreased mortality rate from 18 to 3% [12]
and the Netherlands Cancer Center from 8 to 4% [15]. The
present results also demonstrated the the importance of the
learning curve and the introduction of new technique of
aqua dissection method. The deep invasion or scalloping
into the liver hilum and superior omental recess and diﬀuse
small bowel involvement are the limiting factors to achieve
complete cytoreduction.
We developed an aqua dissection technique to guide
surgeons to perform a safe tumor dissection through the
correct dissection plane, to avoid injury of the important
vessels, and to reduce the blood loss. Using this technique,
the dissection around the hepatic hilar plate and lateral
dissection of the pelvic spaces can be done in a safer and
easier manner.
Diﬀuse small bowel involvement is the most frequent
cause of incomplete cytoreduction. Tumor nodules from
colorectal and gastric cancer often invade the mesentery
where the blood vessels enter the small bowel and this
can be especially problematic to resect the tumor nodules
without full-thickness injury to the bowel. Once the smallGastroenterology Research and Practice 9
Table 4: Survival after CRS in terms of CC score and PCI score.
Median survivals 1-year survival 3-year survival 5-year survival Log-rank test (P)
months (%) (%) (%) X2
Colorectal cancer
CC-0,-1 (N = 62) 38.4 93 51 28 P = 0.003
CC-2,-3 (N = 19) 19.2 33 16 0 X2 = 8.53
PCI ≤ 10 (N = 45) NR 95 59 59 P<0.001
PCI ≥ 11(N = 36) 18.2 83 37 0 X2 = 12.90
Appendiceal
neoplasm
CC-0,-1 (N = 228) NR 99 93 84 P<0.001
CC-2,-3 (N = 192) NR 91 69 50 X2 = 41.48
PCI ≤ 28 (N = 257) NR 99 89 76 P<0.001
PCI ≥ 29 (N = 163) 49.2 87 63 55 X2 = 38.81
Gastric cancer
CC-0,-1 (N = 101) 21.5 70 26 17 P<0.001
CC-2,-3 (N = 65) 13.6 59 8 2 X2 = 14.90
PCI ≤ 6( N = 111) 21.5 76 23 14 P<0.001
PCI ≥ 7( N = 55) 13.6 57 21 3 X2 = 10.48
bowel is inspected completely, a decision is made to per-
form resections while leaving adequate bowel length for
normal nutritional function and minimizing the number of
anastomoses. In colorectal and gastric cancer, the present
data demonstrated that the complete cytoreduction rate in
patients with SB-PCI ≤ 3 was signiﬁcantly higher (85.6%,
15/118) than that in patients with SB-PCI ≤ 4 (32.3%,
20/42). In appendiceal neoplasm patients, CC-0,-1 resection
rate was signiﬁcantly higher in patients with SB-PCI ≤ 6
(209/265, 79%) than that in those with SB-PCI ≥ 7 (19/155,
12%). Accordingly, the SB-PCI thresholds for the complete
cytoreduction were ≥3 for colorectal and gastric cancer and
≥6 for appendiceal neoplasm. Esquivel et al. reported that
there is no surgical option to remove all aﬀected sites of
small bowel even if there is evidence of intestinal obstruction
at more than one site [16]. In colorectal and gastric cancer,
an extended removal of the small bowel will cause not only
a short bowel syndrome but also a recurrence within short
time. Accordingly, the indication for the extensive bowel
resection in colorectal and gastric cancer is limited. On the
contrary, Bao and Bartlett reported that 200cm of small
bowel should be maintained in appendiceal neoplasm. These
results indicate that the extended resection of small bowel is
indicated for the PC from the tumors with a less aggressive
biological behavior, like appendiceal neoplasms.
PCI score demonstrated its signiﬁcant inﬂuence on
survival, and a PCI score capable of serving as a threshold
for favorable versus poor prognosis has been reported. In
colorectalcancer, the survival results were signiﬁcantly better
when the PCI was lower than 16 [17, 18]. Sugarbaker also
reported a 5-year survival rate of 50% when the PCI was less
than 10, a rate of 20% for an index of 11–20, and a rate of 0%
for an index >20 [6]. In gastric cancer, Glehen et al. reported
that no patients were alive even after complete cytoreduction
when the PCI was more than 12. Accordingly, PCI of more
than 12 should be contraindicated for CRS and HIPEC
[13]. The present study demonstrated that the survival of
gastric cancer patients with a PCI ≤ 6 was signiﬁcantly
better than those with a PCI ≥ 7. In contrast, in appendiceal
neoplasm, patients with PCI score ≤ 28 showed signiﬁcant
better survival than those with PCI score ≥ 29. Sugarbaker
reported that the PCI threshold for appendiceal neoplasm
was 20 [4]. Gastric cancer and colorectal cancer have a more
aggressive biological behavior than appendiceal neoplasm,
andpatientswithPCIlargerthanthethresholdvaluesshould
be treated with palliative intent of CRS combined with
systemic chemotherapy.
Recently, neoadjuvant intraperitoneal/systemic chemo-
therapy improves survival results in gastric cancer. Patients
who progress or develop extra-abdominal metastases during
neoadjuvant chemotherapy may be excluded froman aggres-
sive CRS [5]. In addition, intraperitoneal chemotherapy for
gastric cancer is eﬀective to eradicate peritoneal-free cancer
cells and small PC nodules [5]. After IP chemotherapy,
complete disappearance of cancer cells of PC was observed
in 50% of 30 patients with gastric cancer, and also stage
migration from stage 4 to stage 1, 2, or 3 was experienced
in 33% of patients [5]. These results may indicate that the
neoadjuvant chemotherapy can increase the incidence of
complete cytoreduction by eradicating PC nodules before
surgery. In particular, patients with small bowel involvement
should be treated with this strategy before CRS and HIPEC.
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